Sol Barer

Sol Barer is currently an advisor at Waveguide, and previously served as the CEO of Canterbury Labs and Molecular Insight Pharmaceuticals.

Barer was recruited by leading debt and equity investors Highland Capital Management and Morgan Stanley Partners to turn around and restructure Molecular Insight Pharmaceuticals in 2011. In this role, Barer reduced cash burn by more than 20 million dollars, extended the current cash runway by more than 3 quarters, refocused and completely repositioned the company as a prostate cancer entity, negotiated and settled 3 simultaneous law suits, and re-energized the team.

In January 2013, Barer successfully sold Molecular Insight Pharmaceuticals to Nasdaq-listed biotech company Progenics Pharmaceuticals, with upfront, milestone, and royalty payments.

Sol Barer's educational career includes completing an MBA in entrepreneurship, global strategy, and venture capital at Babson F.W. Olin Graduate School of Business, as well as a Bachelor's degree in Philosophy and Biology from the University of Rochester.